跳至主要内容
临床试验/JPRN-jRCT2080220736
JPRN-jRCT2080220736未知3 期

ong-Term Treatment Study of Ocrelizumab for Rheumatoid Arthritis

Chugai Pharmaceutical Co., Ltd.0 个研究点目标入组 200 人开始时间: 2009年5月26日最近更新:
适应症

试验速览

阶段
3 期
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • Subjects who have completed the week 24 visit in the previous study
  • -Treatment with methotrexate (MTX) 6-8mg/week (administered orally) has continued from the previous study.

排除标准

  • -Functional Class 4 as defined by the ACR Classification of Functional Status in rheumatoid arthritis.
  • -Cardiac or pulmonary function worsens markedly from the week 24 visit in the previous study to enrolment in this study.
  • -Primary or secondary immunodeficiency, including HIV infection occurs from the week 24 visit in the previous study to enrolment in this study.
  • -Hepatitis B, hepatitis C or tuberculosis infection occurs from the week 24 visit in the previous study to enrolment in this study.
  • -Malignancy occurs from the week 24 visit in the previous study to enrolment in this study.

研究者

相似试验